All In Biotech

Drug Trial Radar · NCT00185211

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.

Last checked: Nov 20, 2026Latest source record: Dec 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

468

Actual

Start

Aug 2002

Primary completion

May 2008

Study completion May 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 48 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated either after Clinically Definite Multiple Sclerosis (CDMS) has been diagnosed or after two years (those patients who were treated with placebo during the double-blind BENEFIT study). Analyses are based on the integrated data of the initial BENEFIT study and this follow-up study.

Conditions

  • Multiple Sclerosis

Interventions

  • Interferon beta-1b (Betaseron, BAY86-5046)Drug

    Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase

  • Interferon beta-1b (Betaseron, BAY86-5046)Drug

    Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in TimeTime frame: up to 60 months after start of treatment
  2. Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in TimeTime frame: up to 60 months after start of treatment
  3. Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60Time frame: 60 months after start of treatment

Locations

94 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Pilsen, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Glostrup Municipality, Denmark

  • Site not named

    Helsinki, Finland

  • Site not named

    Kuopio, Finland

  • Site not named

    Oulu, Finland

  • Site not named

    Seinäjoki, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Dijon, France

  • Site not named

    Lille, France

  • Site not named

    Nancy, France

  • Site not named

    Nice, France

  • Site not named

    Paris, France

  • Site not named

    Toulouse, France

  • Site not named

    Rennes, Brittany Region, France

  • Site not named

    Bordeaux, Gironde, France

  • Site not named

    Ulm, Baden-Wurttemberg, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Regensburg, Bavaria, Germany

  • Site not named

    Würzburg, Bavaria, Germany

  • Site not named

    Hennigsdorf, Brandenburg, Germany

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.